secwatch.observer — SEC 8-K summary ====================================== Issuer: Alzamend Neuro, Inc. (ALZN) CIK: 0001677077 Form: 8-K Filed at: 2026-11-17T21:30:32+00:00 Accession: 0001214659-26-014504 Event type: regulatory Sentiment: negative Materiality: 0.62 Item codes: 8.01, 9.01 LLM model: deepseek-v4.1-flash:cloud@v2 Alzamend pauses AL001 bipolar trial after FDA rejects enrollment-criteria change; MGH terminates BD SOW -------------------------------------------------------------------------------- - FDA wrote on Oct 15, 2026 that the AL001 bipolar trial design did not appear adequate and well-controlled enough to support an NDA. - Alzamend paused the BD Clinical Trial on Oct 21, 2026 after MGH said co-morbidity exclusions (diabetes, cardiovascular disease, anxiety) hampered enrollment. - MGH terminated the bipolar statement of work on Nov 11, 2026 and will refund about $25,000 in unused funds; the Healthy SOW is unaffected. - Company will seek a Type B FDA meeting on a revised plan expected to drop Phase II and move directly to a Phase III efficacy/safety trial in bipolar; feedback targeted by end of Q2 2027. - Final clinical study report and results for the Healthy Patient Clinical Trial, initiated May 2025 and completed Nov 2025, are expected in December 2026. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465926014504/0001214659-26-014504-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1677077/000121465926014504/o11172648k.htm HTML page: https://secwatch.observer/filing/0001214659-26-014504 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer